201 results about "Intraperitoneal route" patented technology

The invention discloses an establishment method and a verification method of a hydrogen peroxide induced mouse autism model, and relates to the technical field of medical biologication.The establishment method of the hydrogen peroxide induced mouse autism model comprises the following steps that a hydrogen peroxide solution is injected into the abdominal cavity of a pregnant mouse, hydrogen peroxide induction is conducted, and the mouse autism model is obtained. And obtaining a hydrogen peroxide induced offspring mouse, namely the mouse autism model. Hydrogen peroxide is used for near intraperitoneal injection of a female mouse during pregnancy, the oxidative stress state of the female mouse during pregnancy and the oxidative stress state of an offspring mouse embryo are induced through independent hydrogen peroxide, and obvious immune response of the female mouse is not caused, so that an ASD mouse model specifically induced by oxidative stress is formed; the obtained ASD offspring mouse has a remarkable ASD phenotype, but does not show obvious dyskinetic disorder.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

The invention belongs to the technical field of biology, and particularly relates to application of hepcidin expression quantity in larimichthys crocea liver as larimichthys crocea visceral white-spot disease resistance evaluation index and a construction method. The hepcidin expression quantity in the larimichthys crocea liver is applied as the larimichthys crocea visceral white-spot disease resistance evaluation index. The construction method of the resistance evaluation index comprises the following steps: taking healthy small yellow croaker intraperitoneal injection pseudomonas proteinus strain bacterial liquid, and determining a half lethal dose in 96 hours; the method comprises the following steps: injecting a half lethal dose of bacterial liquid of pseudomonas proteinus strains into the abdominal cavity of healthy small yellow croaker for 96 hours, and after infection, taking different tissues to carry out hepcidin gene expression fluorescent quantitative PCR analysis; a regression model of gene expression quantity and bacterium loading quantity is established through fluorescence quantification, and the relationship between hepcidin expression quantity and disease resistance is constructed. Accurate disease-resistant phenotype information is provided for development of breeding of visceral white-spot disease-resistant improved varieties of the small yellow croakers, the accuracy of disease-resistant breeding is promoted, early detection of diseases is realized, and prevention and treatment of the diseases are effectively guided.

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.

The invention discloses an application of a polypeptide Apelin-13 in a medicine for treating psoriasis, in particular to psoriasis-like skin lesion. In an imiquimod (IMQ) cream induced mouse psoriasis model, intraperitoneal injection of Apelin-13 can significantly reduce scale, erythema and skin thickness, and can inhibit proliferation of epithelial spine cells. HE staining and immunohistochemical staining are carried out on the skin tissue of an experimental mouse, and the result shows that Apelin-13 can reduce the expression of the psoriasis marker protein K17, the thickness of the surface layer of the back side skin of the experimental mouse and the downward extension of a spinous layer. Experimental mouse serum ELISA (enzyme-linked immunosorbent assay) detection results show that the Apelin-13 can be used for down-regulating IL-17A (interleukin-17A) which is highly expressed in psoriasis. The polypeptide Apelin-13 can be used as a medicine for treating psoriasis, especially a medicine for treating psoriasis-like skin lesion.

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention discloses application of adenosine deaminase or a modifier thereof in preparation of a medicine for treating diabetic nephropathy. After intraperitoneal injection treatment of polyethylene glycol modified escherichia coli expressed mouse adenosine deaminase is carried out on a mouse with diabetic nephropathy, the damage degree of the kidney of the mouse is obviously weakened. According to the invention, the adenosine deaminase or the modifier thereof has an obvious treatment effect on the type 2 diabetic nephropathy for the first time, and the adenosine deaminase and the modifier thereof have potential application prospects in preparation of the medicines for treating the type 2 diabetic nephropathy.

The invention discloses an acoustic catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts and drug therapy. NJU-319 is selected as an acoustic catalyst, NJU-319Pt is synthesized from a porphyrinyl linker (TAPP) and a hexaphenyl triphenyl unit (HFPTP) under a solvothermal condition, and the H2 generation efficiency of NJU-319Pt can be further improved. After intraperitoneal injection, the nano-drug NJU-319Pt catalyzes H2O to be reduced into H2 under ultrasonic irradiation, and meanwhile lactic acid is oxidized into pyruvic acid. The action mechanism comprises: removing ROS and relieving oxidative stress; by inhibiting an NF-kappa B pathway, the transformation of macrophages from M1 phenotype to M2 phenotype is promoted, and inflammation is reduced; mitochondrial membrane potential is reduced, EMs cell apoptosis is induced, and focus growth is inhibited. The research provides a brand new EMs treatment strategy, combines acoustic catalysis H2 generation with lactic acid oxidation, and provides a new direction for EMs treatment research.

Provided herein are composition, systems, kits, and methods for preventing and / or treating, reversing, and / or inhibiting progression of, a neurodegenerative and / or neurological conditions and / or eye conditions (e.g., retinitis pigmentosa) by administering a plurality of nanoparticles to a subject via subcutaneous, intramuscular, or intraperitoneal injection such that the plurality of nanoparticles are taken up by lymphatic capillaries and are transported to neurological and / or eye tissue of the subject via the subject's lymphatic system, wherein the plurality of nanoparticles encapsulate, or are attached or absorbed to, at least one drug agent.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention relates to the technical field of laboratory devices, in particular to an intelligent intraperitoneal injection auxiliary fixing device for laboratory mice, which comprises a basic bearing module, and a mouse fixing module, a pressure monitoring module, a control module, an indication module and a power supply module which are mounted on the basic bearing module, wherein the mouse fixing module is used for fixing a mouse, the mouse fixing module comprises a lower arc-shaped latticed clamping plate, an upper arc-shaped clamping plate, a connecting piece and a hook lock, the lower arc-shaped latticed clamping plate and the upper arc-shaped clamping plate are connected through the connecting piece, and the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate are jointly matched to clamp the mouse; the abdomen of the mouse faces the lower arc-shaped latticed clamping plate, the hook lock is used for fixing the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate, the pressure monitoring module can monitor the stress condition of the mouse in real time, compressive stress or suffocation of the mouse is avoided, and animal welfare is improved.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention discloses a novel fish oxytocic as well as a use method and application thereof, and belongs to the technical field of fish oxytocic. The novel fish oxytocic takes polypeptide as a main component or an effective component, and the amino acid sequence of the polypeptide is shown as SEQ ID NO.1. After intraperitoneal injection of the novel fish oxytocic provided by the invention, the novel fish oxytocic has a remarkable oxytocic effect on zebrafish and can be applied to ovulation promotion of artificially cultured fishes; the method has important significance in reducing the adverse effect of external adverse environment on fish ovulation, reducing the condition requirements in the fish breeding process, ensuring the stable fry yield of a farm and promoting the healthy development of the fish culture industry; the provided novel fish oxytocic is polypeptide composed of eight amino acids, has no potential safety hazard to fishes and consumers, and has a wide application prospect.

The invention discloses application of Gabapentin in improvement of cognitive impairment of Alzheimer's disease. An application model is an APP / PS1 Alzheimer's disease animal model, a control group is a wild type mouse, Gabapentin granules are dissolved with normal saline and used in an intraperitoneal injection mode, the dosage of single administration is 50 mg / kg, administration is performed for 7 days each month, and then behavioral detection is performed. By detecting and analyzing the actual application result, the effect description of the Gabapentin on the improvement of the AD scene memory is obtained. When the medicine is subjected to intraperitoneal injection and administration, the excessive excitability of neurons can be reduced, the scene memory function of AD mice can be improved, a new use method of Gabapentin is expanded, and a new thought is provided for treatment of AD.

The present invention relates to the technical field of pharmaceuticals and specifically describes an application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The present invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension by means of an HTR1A inhibitor WAY100635 administered at 1 mg / kg / day by intraperitoneal injection or alverine administered at 15 mg / kg / day by oral gavage. A 5-hydroxytryptamine receptor 1A antagonist can be used to prepare an experimental drug for the treatment of cirrhotic portal hypertension. Furthermore, the 5-hydroxytryptamine receptor 1A antagonist can also be used to prepare drugs for symptoms of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy. The present invention provides a novel treatment means to treat the manifestations of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy.

The invention provides an application of combination of IL-28A and Anti-PD-1 antibodies in preparation of colon cancer drugs, and belongs to the technical field of biological medicines. The invention provides an application of IL-28A in preparation of an Anti-PD-1 antibody immune checkpoint sensitizer, and provides an application of combination of the IL-28A and an Anti-PD-1 antibody in preparation of a medicine for treating colon cancer. Through an intraperitoneal injection method, the result shows that the tumor can be gradually reduced and finally disappears when the IL-28A and the Anti-PD-1 are combined for treating the subcutaneous MC38 tumor of a mouse, and a remarkable synergistic effect can be generated when the IL-28A and the Anti-PD-1 antibody are combined for medication, so that the regression of the colon cancer tumor is facilitated.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The invention belongs to the field of biological medicine, particularly discloses pharmaceutical application of a Dio3 inhibitor screened based on a thyroid hormone disorder algorithm in sepsis cardiomyopathy, and discloses that the core pathological mechanism of SIC is thyroid hormone signal axis disorder caused by Dio3 abnormal up-regulation, further mitochondrial autophagy key protein is inhibited, and the application of the Dio3 inhibitor in sepsis cardiomyopathy is developed for the first time. And myocardial mitochondrial homeostasis imbalance and functional cardiac dysfunction are caused. Through single intraperitoneal injection (25mg / kg) of a compound PBENZ-DBRMD (specific Dio3 inhibitor) within 12 hours after sepsis occurs, heart function indexes (EF% / FS%) can be remarkably recovered, and mitochondrial autophagy disorder can be reversed. Meanwhile, serum transT3 (rT3) is provided as an SIC early diagnosis marker (rT3 is strongly negatively correlated with EF%). The scheme provides a new targeted intervention strategy for SIC, and has the characteristics of simplicity and convenience in operation and definite curative effect.

The invention belongs to the technical field of medical biological research, and particularly relates to a construction method of a spontaneous emphysema mouse model. The invention relates to a method for constructing a spontaneous emphysema mouse model, which comprises the following steps: when a Muc1 gene whole body knockout mouse naturally senility for 3-18 months to form spontaneous emphysema and / or a Muc1 type 2 alveolar epithelial cell knockout mouse is 6-8 weeks old, injecting tamoxifen into the intraperitoneal cavity of the mouse to induce knockout. According to the invention, the Muc1 gene knockout mouse is used for constructing a spontaneous emphysema mouse model product for the first time; the related products comprise construction schemes, application transformation and the like of a spontaneous emphysema model generated by Muc1 whole body knockout mouse (Muc1- / -) along with age increase and a spontaneous emphysema model generated by Muc1 type 2 alveolar epithelial cell knockout (Muc1AT2- / -) mouse induced by intraperitoneal injection tamoxifen along with age increase. The invention proves that the spontaneous emphysema model is successfully constructed.

The invention discloses a construction method of an animal model for combined induction and exacerbation of asthma. The method comprises the following steps: injecting ovalbumin or dermatophagoides pteronyssinus extract into an intraperitoneal cavity for sensitization; aerosol inhalation of allergen is carried out for airway re-exposure; in the aggravating stage, pathogenic microorganisms such as pseudomonas aeruginosa, aspergillus fumigatus or respiratory syncytial virus are given and exposed to 500 mu g / m PM2.5 aerosol; lung tissue and bronchoalveolar lavage fluid are then detected. The established model shows that the airway resistance is obviously enhanced and persistent, the mucous thrombus formation rate is greater than 50%, the smooth muscle is obviously thickened, and the model is accompanied by eosinophilic granulocyte and neutrophil infiltration and high expression of various inflammatory factors. The model is good in stability and high in repeatability, can truly simulate clinical asthma acute exacerbation and steroid insensitive characteristics, and provides a platform for asthma mechanism research and new drug screening.

The application belongs to the technical field of medicine and the technical field of brain degenerative diseases, and particularly relates to application of a PHGDH inhibitor NCT-503 in preparation of a medicine for preventing and treating Parkinson's disease, and verifies that specific inhibition of PHGDH can inhibit nerve inflammation in the brain substantia nigra region in vivo, reduce death of dopaminergic neurons, and thus relieve occurrence and development of Parkinson's disease; acute Parkinson's disease model mice are constructed by intraperitoneal injection of MPTP, and it is found that intraperitoneal injection treatment of NCT-503 can effectively reduce MPTP-induced nerve inflammation and reduce death of dopaminergic neurons. In conclusion, it is found for the first time that use of NCT-503 to inhibit PHGDH activity can significantly inhibit MPTP-induced nerve inflammation and reduce death of dopaminergic neurons, which provides an important theoretical basis for clinical application of NCT-503, and also provides a new idea for medicine research and development and screening for treating Parkinson's disease.

The invention discloses an application of an LCN2 protein. The application comprises the following applications: a, an application in preparation of a medicine for improving the plasticity of a visual cortex; b, application in preparation of drugs for treating visual cortex injury related diseases; the administration mode of the medicine is peripheral administration. The invention also discloses a peripherally administered LCN2 protein medicine, which comprises the LCN2 protein and a pharmaceutically acceptable carrier or auxiliary material, the peripheral administration of the LCN2 protein drug can improve the plasticity of the visual cortex and can treat visual cortex injury related diseases. According to the invention, the LCN2 protein is taken as an active ingredient, and a peripheral administration mode of intraperitoneal injection is adopted, so that the LCN2 protein can recover the nearly disappeared eye dominant plasticity of an adult individual, and a new way is provided for treating diseases related to visual cortex injury.

The invention provides an application of alkaloid bicuculline in preparation of a medicine for preventing and / or treating hepatic fibrosis diseases and hepatic inflammation, and also provides an application of bicuculline in preparation of an inflammatory factor expression inhibitor and an application of bicuculline in preparation of a Toll-like receptor 4 signal channel inhibitor. 7.5 mu g / mL of bicuculline can be used for relieving the activation of hepatic stellate cells induced by TGF-beta1, remarkably reducing the expression of alpha-SMA and COL1A1, and reducing the expression of MyD88 and NF-kB as well as downstream inflammatory factors IL-6, IL-1beta and TNF-alpha in a TLR4 / MyD88 / NF-kB signal channel. By intraperitoneal injection treatment of 0.6 mg / kg of bicuculline, the liver morphology in a fibrosis model can be remarkably improved, the levels of ALT and AST in serum can be remarkably reduced, and collagen deposition and expression of alpha-SMA and COL1A1 in the liver can be remarkably reduced.